TR EN AR RU KK

6887Sunshine Lake Pharma Co., Ltd.

Sağlık
🇭🇰 Hong Kong Borsası
41.08
HKD
Analysis Scores
Lothien Robustness Score?
38/100
Weak
Neden bu skor?
Damodaran ?
25/100
Dalio Risk ?
42/100
Piotroski ?
7/9
Strong
Graham ?
HK$10.5
Pahalı
Active Metric?
4/4
Confidence?
72%
Lothien Robustness Summary
45/100
Lothien Sağlamlık: Orta (45/100)
Karışık sinyaller. Hem olumlu hem olumsuz göstergeler mevcut. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 3 | Negatif: 5 | Nötr: 2
Net Kâr Pozitif
Son çeyrekte HK$80M net kâr açıklandı. Şirket kârlı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+231.3 arttı. Büyüme trendi sağlıklı.
Orta Seviye Borç
Net borç/özkaynak 0.73x. Yönetilebilir seviyede ama takip edilmeli.
Likidite Riski
Cari oran 0.77x — kısa vadeli borçları karşılama kapasitesi düşük. Nakit sıkışıklığı riski var.
Güçlü Nakit Üretimi
Serbest nakit akışı (HK$67M) kârın %84'sini nakit olarak üretiyor. Kâr kalitesi yüksek.
Yüksek F/K Uyarısı
Trailing F/K: 73.9. Piyasa yüksek büyüme bekliyor ya da hisse pahalı. Büyüme gerçekleşmezse düşüş riski yüksek.
Yüksek EV/EBITDA
EV/EBITDA: 20.6. Pahalı değerleme.
Düşük ROE
ROE: %3.1. Sermaye getirisi yetersiz — enflasyonun altında.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-21.4 düşebilir. Sonraki bilançoya dikkat.

Data date 2026-10-23 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Method How the scores are computed · Scorecard
Data date 2026-10-23
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Yüksek
252 days
Annual Volatility ?
%53.4
VaR 95% ?
%5.51
daily max loss
VaR 99% ?
%7.80
daily max loss
CVaR 95% ?
%7.06
expected loss (tail)
Max Drawdown ?
%44.9
10.11.2025 → 17.07.2026
Skewness ?
-0.25
Parametrik%5.51
Historik%4.03
Cornish-Fisher%4.82
Return Distribution
Valuation
Potential?
-43.8%
ROIC ?
4.6%
DCF Value ?
5.65
Debt Cycle?
Contraction
Balance Sheet Analysis? Q2026/6
Son 4 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+5.3 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 39.01 HKD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %5.7
Net profit margin %5.7 — positive but low. Compared to previous quarter +0.0 point increase.
ROE - Return on Equity (TTM) %3.1
ROE %3.1 — low return on equity.
EBITDA Margin %23.5
EBITDA margin %23.5 — good operational performance.
Gross Profit Margin %76.5
Gross profit per revenue %76.5. Strong pricing power.
Free Cash Flow Margin (TTM) %4.7
TTM Free Cash Flow is %4.7'i. Moderate FCF — capex constraining operational profit.
Valuation
P/E Ratio 73.9x Sector: 20.0x
F/K 73.9x — sector median's (20.0x) %270 above. Expensive zone.
P/B Ratio 4.64x Sector: 2.38x
PD/DD 4.64x — sector median's %95 above. Expensive book value.
EV/EBITDA 20.6x Sector: 11.2x
EV/EBITDA 20.6x — sector median's (11.2x) %85 above. Expensive relative to EBITDA.
Indebtedness
Current Ratio 0.77x
Current ratio 0.77x — short-term liabilities exceed current assets. Liquidity risk.
Net Debt / EBITDA 4.1x
Net Debt/EBITDA 4.1x — high debt burden. Debt service creating pressure.
Debt / Equity 1.08x
Debt/Equity 1.08x — moderate financial leverage.
Interest Coverage 5.0x
Interest coverage 5.0x — interest obligations comfortably covered.
Growth
Revenue Growth (YoY) %+19.8
Revenue YoY %19.8 grew — healthy growth rate.
Net Profit Growth (YoY) %+231.3
Net profit turned from loss to profit (2025/12). Significant improvement.
Score Explanations
Lothien Robustness
38/100
Weak robustness (38/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Weak
Potential
-43.8%
Minus %43.8 expected value (23.10) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %72.
Components: PE target: 10.52 | P/B target: 21.37 | EV/EBITDA target: 22.24 | DCF target: 10.27
Damodaran Valuation
25/100
Low Damodaran score (25/100). ROIC (%4.6) below cost of capital. DCF analysis does not support current price.
Very Weak
Dalio Risk Analysis
42/100
High debt risk (42/100). Interest coverage ratio 5.0x — acceptable. Debt/EBITDA 4.1x — high debt burden.
Leverage: 32/100 | Debt Service: 63/100 | Quality: 45/100
ROIC - Return on Capital
%4.6
ROIC (%4.6) cost of capital (8.2%) below → destroying value.
WACC: %8.2
DCF Discounted Cash Flow
5.65
DCF (5.65) current price %86.2 below — cash flows do not support current price.
Current price: 41.08
Debt Cycle Phase
Contraction
High debt service + falling revenues. Balance sheet under pressure.
Piotroski F-Score
7/9
Strong Piotroski F-Score (7/9). Profitability, leverage and operational efficiency criteria are largely met.
Strong
Graham Intrinsic Value
HK$10.5
Expensive
⚖️ Sector Comparison
P/E Ratio
73.9x vs 20.0x
Sector median's %270 above — expensive
P/B Ratio
4.64x vs 2.38x
Compared to sector %95 more expensive (by book value)
EV/EBITDA
20.6x vs 11.2x
Compared to sector %85 higher EV/EBITDA
ROIC vs WACC
%4.6 vs %8.2 WACC
ROIC 3.7 bps below cost of capital
Net Profit Margin (TTM)
%5.7 vs %23.5 EBITDA margin
TTM net profit margin %5.7
TRAMA-99 Trend — Uptrend
Price (41.08), TRAMA-99 line's %5.3 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 41.08
TRAMA: 39.01
Difference: %+5.3
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
6887 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.